Replies to post #312326 on Avid Bioservices Inc (CDMO)

[biopharm]

The Enlightenment Age of Disease....

Are we getting closer to proving what targeting flipped PS helps re: homeostasis ?

Publicatienummer EP1826278 A1
Publicatietype Aanvraag
Aanvraagnummer EP20070004137
Publicatiedatum 29 aug 2007
Aanvraagdatum 28 feb 2007
Prioriteitsdatum 28 feb 2006
Ook gepubliceerd als DE602007014278D1, Nog 4 meer »
Uitvinders Sven Olek, Ivana Türbachova
Aanvrager Epiontis GmbH
...
...
...

Background of the invention
[0003]
Regulatory T cells play an important role for the maintenance of immunological tolerance by suppressing the action of autoreactive effector cells, making them interesting targets for therapeutic applications. Therefore, these cells are critically involved in preventing the development of autoimmune reactions (Sakaguchi, Nat Immunol 6:345-352, 2005). Regulatory T cells (Tregs), which have been shown to play a pivotal role in the maintenance of self-tolerance within the immune system, were described originally as CD4+ T cells constitutively expressing CD25 (Sakaguchi, S. Naturally arising CD4+ regulatory T cells for immunologic selftolerance and negative control of immune responses. Annu Rev Immunol 22, 531-562 (2004)). More recently, the forkhead transcription factor Foxp3 has been shown to be specifically expressed in Tregs and to be a central control element in Treg development and function (Fontenot, J.D. and Rudensky, A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6, 331-7 (2005)). Mutation or deletion of the gene encoding Foxp3 causes severe autoimmune disease in mice and humans, due to a failure to generate CD25+CD4+ Tregs (Bennett, C.L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27, 20-1 (2001). Fontenot, J.D., Gavin, M.A. and Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330-6 (2003)), whereas ectopic expression of Foxp3 in conventional T cells confers suppressive activity (Fontenot, J.D., Gavin, M.A. and Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330-6 (2003). Hori, S., Nomura, T. and Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-61 (2003)).
[0004]
These findings provided compelling evidence that Foxp3 acts as a master switch controlling the development and function of Tregs; however, the molecular mechanisms leading to its induction remain largely unknown.
..
..
http://www.google.sr/patents/EP1826278A1?cl=en&hl=nl

[biopharm]

After reading this patent more closely....this "upstream" looks like it could be referring to Phosphatidylserine and now more interesting is the Epiontis collaboration with Peregrine and Turbachova laboratory

The below conference was just in June 2017 and I was surprised to see Epiontis there ....as they discuss secondary endpoints and now imagine those secondary endpoints coming Peregrine's way......also note JUNO presence

...
CHARACTERIZATION OF HUMAN TUMORS

9:00 Chairperson’s Opening Remarks
Travis Beckett, M.S., Scientist, Flow Cytometry Team Lead, Technology Research & Development, Juno Therapeutics
...
..
DETERMINANTS OF TUMOR-IMMUNE INTERACTION

1:40 Chairperson’s Remarks
Thomas Oliver Kleen, Ph.D., Executive Vice President, Immune Monitoring, Epiontis GmbH
..
..

2:20 Immuno-Oncology Trials - Next Generation Immune Monitoring Tools as a Way Forward
Thomas_KleenThomas Oliver Kleen, Ph.D., Executive Vice President, Immune Monitoring, Epiontis GmbH
Monitoring both systemic changes in the blood and intra-tumoral leukocyte subpopulations will be crucial for identifying potential early surrogate markers of immunotherapy treatment success, ultimately paving the way to acceptable secondary endpoints for future Immuno-Oncology trials. Logistics, sample requirements, stability of cells in blood samples and tissue and cost considerations often preclude the use of standard monitoring assays. Novel technologies allow precise and robust quantitation of immune cells in all human samples from only small amounts of blood or tissue.
...
..
http://www.worldpreclinicalcongress.com/Cell-analysis-immunotherapy/